BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Orsan lysine and feed
additives
Orsan lysine and amino acid
feed additives
Sankyo Co. Ltd. development,
manufacturing and
marketing of AJD101
and related compounds
Scotia Holdings
plc
Scotia's SC103 for
treating diabetes
complications
Senomyx Inc. discovery and
development of novel
flavor ingredients
Seragen Inc. IL-2 gene patents for
fusion toxin
Tadamitsu
Kishimoto
PRODUCTS ON MARKET: Food products
Amino acids
Pharmaceuticals
Akzo Nobel NV
joint venture called
Heartland Lysine,
Inc.
joint venture called
Eurolysine
exclusive global
licensing agreement
development and
marketing
agreement--
Ajinomoto gets
exclusive rights in
Japan and several
other Asian
countries, Scotia
gets up-front fee and
milestones
R&D,
commercialization
and licensing
worldwide licensing
agreements (12/94),
restructured to
reduce and defer
Seragen's financial
obligations to
Ajinomoto (including
royalties on product
sales), Seragen's
partner Eli Lilly has
signed separate
licensing agreement
with Ajinomoto and
assumed most of
Seragen's remaining
obligations to
Ajinomoto
IL-6 joint research
agreement
Velperweg 76, P.O. Box 9300
Arnhem 6824 BM, Netherlands
Phone: +31 26 366 44 33; Fax: +31 26 3663250
Web: www.akzonobel.com; E-mail: acc@akzonobel.com
KEY PERSONNEL: Hans Wijers; Chairman and CEO
Rob Frohn; CFO
Keith Nichols; Sr. VP, Finance
EMPLOYEES: 61,500 employees
Copyright ©2006 AHC Media ® 29
8/06
3/97
3/06
6/97
2/97